Oncomatryx Biopharma, S.l.

Cristina Ferrer

Roland Kontermann

Klaus Pfizenmaier

Laureano Simon

Myriam Fabre

The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I:A-(L-D)p&#x2003;&#x2003;(I)or a pharmaceutically acceptable salts or solvates thereof,wherein:A is an antibody that selectively binds FAP;L is a linker;D is a drug comprising a cytolysin or a Nigrin-b A-chain; andp is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Antibody-drug conjugates and immunotoxins

The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Growing community of inventors

Madrid, Spain

Cristina Ferrer